Atlas of Genetics and Cytogenetics

in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS

Gene Section Review

BCLAF1 (BCL2-associated transcription factor 1) John Peter McPherson Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, M5S 1A8 Canada (JPM)

Published in Atlas Database: June 2011 Online updated version : http://AtlasGeneticsOncology.org/Genes/BCLAF1ID43164ch6q23.html DOI: 10.4267/2042/46079 This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence. © 2011 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Identity Transcription Two transcripts 5 kb and 3 kb in length are Other names: BTF; KIAA0164; bK211L9.1 predominantly detected, however additional variant HGNC (Hugo): BCLAF1 transcripts have been described with alternative Location: 6q23.3 promoters, cassette exons and polyadenylation sites. Local order: Orientation on minus strand, flanked by Pseudogene FAM54A and MAP7 (according to GeneLoc and NCBI None identified. Map Viewer). Note: BCLAF1 was originally identified as a protein Protein partner for adenoviral E1B 19K. Forced expression of BCLAF1 causes cell death which is reversed in the Description presence of anti-apoptotic BCL-2. BCLAF1 was At least 4 isoforms are generated by alternative reported to associate in vitro with BCL-2 and BCL2L1. splicing. Two predominant BCLAF1 forms were BCLAF1 was also reported to bind DNA and repress initially described: a longer isoform 920 amino acids in transcription. Taken together, these findings suggested length with a predicted molecular mass of 106 kDa, and a role for BCLAF1 in apoptotic signalling and a smaller isoform missing 49 amino acids (residues transcriptional repression (Kasof et al., 1999). 797-846) with a predicted molecular mass of 101 kDa Subsequent studies using BCLAF1-depleted or Bclaf1- (Kasof et al., 1999). Residues 110-126 exhibit 88% deficient cells do not reveal a critical role for BCLAF1 homology to the bZIP DNA binding domain (Kasof et in death signalling (Ziegelbauer et al., 2009; al., 1999). Residues 522-531 exhibit 80% homology to McPherson et al., 2009). Recent studies have suggested the Myb DNA binding domain (Kasof et al., 1999). roles for BCLAF1 in processes of RNA metabolism Functional evidence for both of these domains remains (Bracken et al., 2008; Sarras et al., 2010), KSHV viral to be shown. The N-terminal region (residues 3-161) of production (Ziegelbauer et al., 2009), lung BCLAF1 is arginine- and serine-rich (RS domain). The development and T cell activation (McPherson et al., C-terminal region (residues 512-913) is 59% similar to 2009; Kong et al., 2011). the C-terminal region of thyroid hormone receptor associated protein 3 (THRAP3/TRAP150). DNA/RNA Expression Description BCLAF1 is ubiquitously expressed, with high steady- The BCLAF1 gene is composed of 13 exons and spans state mRNA levels in skeletal muscle, 32989 bases.

Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10) 994 BCLAF1 (BCL2-associated transcription factor 1) McPherson JP

Protein domains in BCLAF1 L and BCLAF1 S isoforms. haematopoietic cells, and various other cell lineages Bclaf1-deficient cells were found to exhibit altered (Kasof et al., 1999; McPherson et al., 2009). Steady- preferences for alternative splicing of a model substrate state levels of BCLAF1 protein fluctuate in a temporal (Sarras et al., 2010). BCLAF1 was found associated and cell-lineage dependent fashion during development with SkIP, TRAP150 and Pinin in a complex known as (McPherson et al., 2009). SNIP1. SNIP1 was found to regulate cyclin D1 mRNA Localisation processing by facilitating the recruitment of the RNA processing factor U2AF65 to cyclin D1 mRNA Bclaf1 is concentrated in punctate foci interspersed (Bracken et al., 2008). through the nucleus. In the presence of E19K and BCLAF1 has been shown to complex with the RNA conditions which trigger apoptosis, the nuclear export factor TAP/NXF1 (Sarras et al., 2010). This distribution of Bclaf1 appears to concentrate at the property has also recently been reported for TRAP150, nuclear periphery or envelope (Kasof et al., 1999; a protein showing structural similarity to BCLAF1 that Haraguchi et al., 2004). also is found in ribonucleoprotein complexes (Lee et Bclaf1 was identified as a protein component of al., 2010). TRAP150 has been shown to promote pre- interchromatin granular clusters, subnuclear structures mRNA splicing of reporter substrates and promotes that appear to serve as repositories for pre-mRNA mRNA decay in a manner that is independent of splicing factors (Misteli and Spector, 1998; Sutherland nonsense-mediated decay of mRNA (Lee et al., 2010). et al., 2001; Saitoh et al., 2004). Regulation Function Sirt1 has been shown to exert transcriptional control of BCLAF1 at the promoter level (Kong et al., 2011). The exact molecular function of BCLAF1 remains to Sirt1 was found to form a complex with the histone be defined. BCLAF1 was originally identified as acetyltransferase p300 and NF-kB transcription factor having properties of a death-inducing transcriptional Rel-A, bind the BCLAF1 promoter and suppress repressor (Kasof et al., 1999). Several subsequent BCLAF1 transcription via H3K56 deacetylation (Kong studies have expanded on the link between BCLAF1, et al., 2011). transcription and apoptosis. Depletion of BCLAF1 was BCLAF1 protein levels fluctuate according to cell reported to render cells resistant to ceramide-induced cycle position, with levels highest during the G1 phase, apoptosis (Renert et al., 2009). Protein kinase C delta- but lower during S and G2 phases (Bracken et al., mediated transactivation of p53 transcription has been 2008). BCLAF1 protein levels also fluctuate in a cell- shown to occur through the stimulation of BCLAF1 to lineage and temporal manner during differentiation of co-occupy a core promoter element in the TP53 certain tissues and organs (McPherson et al., 2009). promoter (Liu et al., 2007). A role for Bclaf1 in lung Several studies have determined that Bclaf1 is development and T cell homeostasis was demonstrated extensively phosphorylated, although the functional in Bclaf1-deficient mice (McPherson et al., 2009). significance of this modification is unclear. BCLAF1 Bclaf1 was shown to be required for the proper spatial has been proposed as a substrate of GSK-3 kinase and temporal organization of smooth muscle lineage (Linding et al., 2007). Vasopressin action in kidney cells during the saccular stage of lung development. cells has been reported to simulate BCLAF1 Bclaf1 was also shown to be critical for T cell phosphorylation (Hoffert et al., 2006). activation. The phenotype of these mice could not be BCLAF1 has been shown to be one of the cellular explained by a defect in apoptosis, furthermore Bclaf1- targets for microRNAs (miRNAs) encoded by Kaposi's deficient cells displayed no defect in cell death sarcoma-associated herpesvirus (KSHV). KSHV following exposure to various apoptotic stimuli. triggers certain acquired immune deficiency syndrome- Recent studies have implicated BCLAF1 in processes related malignancies such as Kaposi's sarcoma, primary linked to RNA metabolism. BCLAF1 contains an RS effusion lymphoma and variants of multicentric domain, a feature of many factors that facilitate pre- Castleman disease. A miRNA cluster within the KSHV mRNA splicing and mRNA processing. BCLAF1 was genome is expressed during viral latency. During found to be a component of ribonucleoprotein induction of lytic KSHV growth, inhibition of miRNAs complexes (Merz et al., 2007; Sarras et al., 2010). was associated with increased BCLAF1 expression and

Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10) 995 BCLAF1 (BCL2-associated transcription factor 1) McPherson JP

decreased KSHV virion production (Ziegelbauer et al., 2009). Implicated in Interactions X-linked recessive Emery-Dreifuss E1B 19K. By yeast two-hybrid analysis, BCLAF1 was muscular dystrophy shown to directly interact with adenoviral E1B 19K via a BH3 domain and another region immediately Note adjacent to BH3 in E1B 19K (Kasof et al., 1999). In Bclaf1 has also recently been identified as a binding vitro binding assays reported BCLAF1 associates with partner for emerin, a nuclear membrane protein that is BCL-2 and BCL2L1. mutated in X-linked recessive Emery-Dreifuss emerin. By yeast-two hybrid analysis and microtiter muscular dystrophy. Disease mutations in emerin were well binding assays, BCLAF1 was shown to directly found to disrupt the interaction of emerin with interact with emerin, a nuclear membrane protein. BCLAF1 (Haraguchi et al., 2004). Mutations that result in a loss of functional emerin Disease cause X-linked recessive Emery-Dreifuss muscular Emerin is encoded by the EMD gene located on human dystrophy. The residues of emerin required for binding X-chromosome, which when mutated, gives rise to the to BCLAF1 mapped to two regions that flank its lamin- X-linked form of Emery-Dreifuss muscular dystrophy binding domain. Two disease-causing mutations in (Bione et al., 1994). Emerin is a lamin A/C binding emerin, S54F and Delta95-99, disrupted binding to protein that participates in nuclear envelope mechanics BCLAF1. BCLAF1 and emerin were observed to co- which impact chromosome segregation, gene localize in the vicinity of the nuclear envelope expression and muscle differentiation (Liu et al., 2003; following induction of apoptosis by Fas antibody Frock et al., 2006). (Haraguchi et al., 2004). MAN1. The C-terminal domain of MAN1, a nuclear Choroid plexus papillomas inner membrane protein that inhibits Smad signaling Note downstream of transforming growth factor beta, was Up-regulation of BCLAF1 was observed in seven cases observed to bind BCLAF1, as well as the of choroid plexus papilloma cells compared to eight transcriptional regulators GCL, and barrier-to- cases of normal choroid plexus epithelial cells autointegration factor (BAF) (Mansharamani and (Hasselblatt et al., 2009). Wilson, 2005). Disease Factors that participate in RNA metabolism. Choroid plexus papillomas are rare intraventricular BCLAF1 and TRAP150 have been identified to be papillary neoplasms, typically in children and young protein components of ribonucleoprotein complexes adults. that participate in pre-mRNA splicing and other mRNA processing events (Merz et al., 2007; Sarras et al., Non-Hodgkin's lymphoma (NHL) 2010; Lee et al., 2010). Both BCLAF1 and TRAP150 Note have been reported to reside in protein complexes that An association of BCLAF1 single nucleotide contain the mRNA export factor NXF1/TAP (Sarras et polymorphisms (tagSNPs rs797558 and rs703193, P = al., 2010; Lee et al., 2010). Both BCLAF1 and 0.0097) with NHL was made following genotyping of TRAP150, together with Pinin and SkIP, have been 441 newly diagnosed NHL cases and 475 frequency- found in a protein complex that regulates cyclin D1 matched controls (Kelly et al., 2010). mRNA stability. Disease Homology Non-Hodgkin's lymphoma refers to several subtypes of BCLAF1 shares amino acid similarity (48% overall lymphoma that are distinct from Hodgkin's lymphoma, identity) with TRAP150 in their C-terminal domains. such as Mantle cell lymphoma, diffuse large B cell Both proteins also contain RS-rich tracts within their lymphoma and follicular lymphoma (Sawas et al., N-termini (Lee et al., 2010). 2011). Mutations Chondromyxoid fibroma (CMF) Note Note No changes in BCLAF1 were found in 43 samples of BCLAF1 is located at chromosome 6q23 , a region that CMF (Romeo et al., 2010). has been reported to exhibit a high frequency of Disease deletions in tumours, such as lymphomas and Chondromyxoid fibroma (CMF) is an uncommon leukemias. BCLAF1 has observed to be absent in Raji benign cartilaginous tumor of bone usually occurring in cells, derived from Burkitt's lymphoma, which has adolescents (Ralph, 1962; Romeo et al., 2009). CMF is deletions in 6q (Kasof et al., 1999). A role for the loss associated with recurrent rearrangements of of BCLAF1 in neoplastic transformation remains to be chromosome bands 6p23-25, 6q12-15, and 6q23-27. determined and may be coincidental.

Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10) 996 BCLAF1 (BCL2-associated transcription factor 1) McPherson JP

Bracken CP, Wall SJ, Barré B, Panov KI, Ajuh PM, Perkins References ND. Regulation of cyclin D1 RNA stability by SNIP1. Cancer Res. 2008 Sep 15;68(18):7621-8 RALPH LL. Chondromyxoid fibroma of bone. J Bone Joint Surg Br. 1962 Feb;44-B:7-24 Hasselblatt M, Mertsch S, Koos B, Riesmeier B, Stegemann H, Jeibmann A, Tomm M, Schmitz N, Wrede B, Wolff JE, Zheng Bione S, Maestrini E, Rivella S, Mancini M, Regis S, Romeo G, W, Paulus W. TWIST-1 is overexpressed in neoplastic choroid Toniolo D. Identification of a novel X-linked gene responsible plexus epithelial cells and promotes proliferation and invasion. for Emery-Dreifuss muscular dystrophy. Nat Genet. 1994 Cancer Res. 2009 Mar 15;69(6):2219-23 Dec;8(4):323-7 McPherson JP, Sarras H, Lemmers B, Tamblyn L, Migon E, Misteli T, Spector DL. The cellular organization of gene Matysiak-Zablocki E, Hakem A, Azami SA, Cardoso R, Fish J, expression. Curr Opin Cell Biol. 1998 Jun;10(3):323-31 Sanchez O, Post M, Hakem R. Essential role for Bclaf1 in lung Kasof GM, Goyal L, White E. Btf, a novel death-promoting development and immune system function. Cell Death Differ. transcriptional repressor that interacts with Bcl-2-related 2009 Feb;16(2):331-9 proteins. Mol Cell Biol. 1999 Jun;19(6):4390-404 Rénert AF, Leprince P, Dieu M, Renaut J, Raes M, Bours V, Sutherland HG, Mumford GK, Newton K, Ford LV, Farrall R, Chapelle JP, Piette J, Merville MP, Fillet M. The proapoptotic Dellaire G, Cáceres JF, Bickmore WA. Large-scale C16-ceramide-dependent pathway requires the death- identification of mammalian proteins localized to nuclear sub- promoting factor Btf in colon adenocarcinoma cells. J compartments. Hum Mol Genet. 2001 Sep 1;10(18):1995-2011 Proteome Res. 2009 Oct;8(10):4810-22 Liu J, Lee KK, Segura-Totten M, Neufeld E, Wilson KL, Romeo S, Hogendoorn PC, Dei Tos AP. Benign cartilaginous Gruenbaum Y. MAN1 and emerin have overlapping function(s) tumors of bone: from morphology to somatic and germ-line essential for chromosome segregation and cell division in genetics. Adv Anat Pathol. 2009 Sep;16(5):307-15 Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2003 Apr Ziegelbauer JM, Sullivan CS, Ganem D. Tandem array-based 15;100(8):4598-603 expression screens identify host mRNA targets of virus- Haraguchi T, Holaska JM, Yamane M, Koujin T, Hashiguchi N, encoded microRNAs. Nat Genet. 2009 Jan;41(1):130-4 Mori C, Wilson KL, Hiraoka Y. Emerin binding to Btf, a death- Kelly JL, Novak AJ, Fredericksen ZS, Liebow M, Ansell SM, promoting transcriptional repressor, is disrupted by a missense Dogan A, Wang AH, Witzig TE, Call TG, Kay NE, Habermann mutation that causes Emery-Dreifuss muscular dystrophy. Eur TM, Slager SL, Cerhan JR. Germline variation in apoptosis J Biochem. 2004 Mar;271(5):1035-45 pathway genes and risk of non-Hodgkin's lymphoma. Cancer Saitoh N, Spahr CS, Patterson SD, Bubulya P, Neuwald AF, Epidemiol Biomarkers Prev. 2010 Nov;19(11):2847-58 Spector DL. Proteomic analysis of interchromatin granule Lee KM, Hsu IaW, Tarn WY. TRAP150 activates pre-mRNA clusters. Mol Biol Cell. 2004 Aug;15(8):3876-90 splicing and promotes nuclear mRNA degradation. Nucleic Mansharamani M, Wilson KL. Direct binding of nuclear Acids Res. 2010 Jun;38(10):3340-50 membrane protein MAN1 to emerin in vitro and two modes of Romeo S, Duim RA, Bridge JA, Mertens F, de Jong D, Dal Cin binding to barrier-to-autointegration factor. J Biol Chem. 2005 P, Wijers-Koster PM, Debiec-Rychter M, Sciot R, Rosenberg Apr 8;280(14):13863-70 AE, Szuhai K, Hogendoorn PC. Heterogeneous and complex Frock RL, Kudlow BA, Evans AM, Jameson SA, Hauschka SD, rearrangements of chromosome arm 6q in chondromyxoid Kennedy BK. Lamin A/C and emerin are critical for skeletal fibroma: delineation of breakpoints and analysis of candidate muscle satellite cell differentiation. Genes Dev. 2006 Feb target genes. Am J Pathol. 2010 Sep;177(3):1365-76 15;20(4):486-500 Sarras H, Alizadeh Azami S, McPherson JP. In search of a Hoffert JD, Pisitkun T, Wang G, Shen RF, Knepper MA. function for BCLAF1. ScientificWorldJournal. 2010 Jul Quantitative phosphoproteomics of vasopressin-sensitive renal 20;10:1450-61 cells: regulation of aquaporin-2 phosphorylation at two sites. Kong S, Kim SJ, Sandal B, Lee SM, Gao B, Zhang DD, Fang Proc Natl Acad Sci U S A. 2006 May 2;103(18):7159-64 D. The type III histone deacetylase Sirt1 protein suppresses Linding R, Jensen LJ, Ostheimer GJ, van Vugt MA, Jørgensen p300-mediated histone H3 lysine 56 acetylation at Bclaf1 C, Miron IM, Diella F, Colwill K, Taylor L, Elder K, Metalnikov promoter to inhibit T cell activation. J Biol Chem. 2011 May P, Nguyen V, Pasculescu A, Jin J, Park JG, Samson LD, 13;286(19):16967-75 Woodgett JR, Russell RB, Bork P, Yaffe MB, Pawson T. Sawas A, Diefenbach C, O'Connor OA. New therapeutic Systematic discovery of in vivo phosphorylation networks. Cell. targets and drugs in non-Hodgkin's lymphoma. Curr Opin 2007 Jun 29;129(7):1415-26 Hematol. 2011 Jul;18(4):280-7 Liu H, Lu ZG, Miki Y, Yoshida K. Protein kinase C delta induces transcription of the TP53 tumor suppressor gene by This article should be referenced as such: controlling death-promoting factor Btf in the apoptotic response McPherson JP. BCLAF1 (BCL2-associated transcription factor to DNA damage. Mol Cell Biol. 2007 Dec;27(24):8480-91 1). Atlas Genet Cytogenet Oncol Haematol. 2011; 15(12):994- Merz C, Urlaub H, Will CL, Lührmann R. Protein composition of 997. human mRNPs spliced in vitro and differential requirements for mRNP protein recruitment. RNA. 2007 Jan;13(1):116-28

Atlas Genet Cytogenet Oncol Haematol. 2010; 14(10) 997